Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach. Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research Enara Bio adds further world-class cell therapy and immuno-oncology expertise to Senior Management Team and Scientific Advisory Board Dr Erik Rutjens appointed as Vice President, Cell Therapy Operations Dr Sadik Kassim and Dr Michael Quigley strengthen Scientific Advisory Board with deep industry experience Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies Enara’s move from the Oxford BioEscalator to one of the UK's largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program. Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5. Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies This new name reflects the company’s expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence “Ervaxx”). Ervaxx and Cardiff University enter collaboration to develop novel T-cell and T-cell receptor-based immunotherapeutics targeting Dark Antigens™ Collaboration also focuses on exciting research published earlier this week in Nature Immunology identifying MR1 as a target for novel anti-cancer immunotherapies Ervaxx presents research identifying melanoma-specific Dark Antigens™ at SITC 2019. CSO Dr. Ray Jupp presented data on Ervaxx’s lead program at the 34th Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, MD, USA on Saturday 9th November 2019. Ervaxx launches to pioneer the use of Dark Antigens™ for the development of off-the-shelf cancer vaccines and T-cell receptor- based immunotherapies Ervaxx coincides its launch with the presentation of new research to identify novel melanoma-specific Dark Antigens by application of its novel EDAPT™ platform at The Society for Immunotherapy of Cancer 34th Annual Meeting (SITC).